Abstract
The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
Keywords: HCV, NS5A, antivirals, HCV inhibitors, hyperphosphorylation
Recent Patents on Anti-Infective Drug Discovery
Title: NS5A - From Obscurity to New Target for HCV Therapy
Volume: 3 Issue: 2
Author(s): Uli Schmitz and Seng-Lai Tan
Affiliation:
Keywords: HCV, NS5A, antivirals, HCV inhibitors, hyperphosphorylation
Abstract: The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
Export Options
About this article
Cite this article as:
Schmitz Uli and Tan Seng-Lai, NS5A - From Obscurity to New Target for HCV Therapy, Recent Patents on Anti-Infective Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489108784746597
DOI https://dx.doi.org/10.2174/157489108784746597 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Viruses in Semen and Male Genital Tissues - Consequences for the Reproductive System and Therapeutic Perspectives
Current Pharmaceutical Design Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Current Drug Targets In Vitro Methods to Study the Interplay of Drug Metabolism and Efflux in the Intestine
Current Drug Metabolism Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Sustained Transgene Expression Using Non-Viral Enzymatic Systems for Stable Chromosomal Integration
Current Gene Therapy